Main > ONCOLOGY (**) > NasoPharingeal Carcinoma (NPC) > TREAT.: > CN. B. Anti PD-1 MAb+CT

---

CN. B. Anti PD-1 MAb+CT's subsections
(*) CN Approval Date: 2022. 06.10
Company
Generic Name: TislelizuMAb
Locally Recurrent or Metastatic
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 6
Patent>UpDate: 2022. 07.05
PR Web-Site

CN. B. Anti PD-1 MAb+CT's products
This section has no products